NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
11.41
-0.35 (-2.98%)
Mar 27, 2026, 9:40 AM EDT - Market open
NovoCure Revenue
In the year 2025, NovoCure had annual revenue of $655.35M with 8.28% growth. NovoCure had revenue of $174.35M in the quarter ending December 31, 2025, with 8.11% growth.
Revenue (ttm)
$655.35M
Revenue Growth
+8.28%
P/S Ratio
2.04
Revenue / Employee
$408,320
Employees
1,605
Market Cap
1.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 655.35M | 50.13M | 8.28% |
| Dec 31, 2024 | 605.22M | 95.88M | 18.82% |
| Dec 31, 2023 | 509.34M | -28.50M | -5.30% |
| Dec 31, 2022 | 537.84M | 2.81M | 0.53% |
| Dec 31, 2021 | 535.03M | 40.67M | 8.23% |
| Dec 31, 2020 | 494.37M | 143.05M | 40.72% |
| Dec 31, 2019 | 351.32M | 103.25M | 41.62% |
| Dec 31, 2018 | 248.07M | 71.04M | 40.13% |
| Dec 31, 2017 | 177.03M | 94.14M | 113.57% |
| Dec 31, 2016 | 82.89M | 49.80M | 150.52% |
| Dec 31, 2015 | 33.09M | 17.60M | 113.60% |
| Dec 31, 2014 | 15.49M | 5.13M | 49.53% |
| Dec 31, 2013 | 10.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AdaptHealth | 3.24B |
| QuidelOrtho | 2.73B |
| Enovis | 2.25B |
| CONMED | 1.37B |
| Tandem Diabetes Care | 1.01B |
| Lumexa Imaging Holdings | 1.00B |
| Inspire Medical Systems | 911.98M |
| UFP Technologies | 602.80M |
NVCR News
- 22 hours ago - NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer - Benzinga
- 1 day ago - Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer - Business Wire
- 25 days ago - Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer - Business Wire
- 27 days ago - Novocure to Participate in 2026 Leerink Global Healthcare Conference - Business Wire
- 4 weeks ago - NovoCure Limited (NVCR) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update - Business Wire
- 4 weeks ago - Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer) - Business Wire
- 6 weeks ago - NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity Approaching - Seeking Alpha